AHP | Syntax PharmaShares AbbVie-Humira Index
The Syntax PharmaShares Indices are designed to track in combination the performances of a pharmaceutical company’s share price and the portion of the reported global net sales of that company’s lead drug that are owned and accrued for the benefit of the company.
The Syntax PharmaShares AbbVie-Humira Index tracks the combined performance of AbbVie Inc.’s listing of common stock shares (ABBV) on the New York Stock Exchange (NYSE) and the revenue of the pharmaceutical drug Humira (also known as adalimumab) that are owned and accrued for the benefit of AbbVie Inc.
Index Facts
| Number of Constituents | 2 |
| Weighting Methodology | Equal |
| Rebalancing Frequency | Quarterly |
| Currency | USD |
| Exchange Symbol/Ticker | AHP |
| Index Inception Date | December 28, 2022 |
| Total Return Index Value as of 05/03/2024 | 3368.95 |
Index Performance
Past performance is no guarantee of future results. The inception date of the Syntax PharmaShares AbbVie-Humira Index (the “Index”) is December 28, 2022. Charts and graphs are provided for illustrative purposes only.
The Index is the property of PharmaShares LLC and Syntax, LLC, which calculates and maintains the Index. Syntax, LLC will not be liable for any errors or omissions in calculating the Index.
Index performance does not represent actual fund or portfolio performance and such performance does not reflect the actual investment experience of any investor. An investor cannot invest directly in an index. In addition, the results actual investors might have achieved would have differed from those shown because of differences in the timing, amounts of their investments, and fees and expenses associated with an investment in a portfolio invested in accordance with an index. Neither the Index nor any benchmark indices portrayed herein charge management fees or incur brokerage expenses, and no such fees or expenses were deducted from the performance shown; provided, however, that the returns of any investment portfolio invested in accordance with such indices would be net of such fees and expenses. Additionally, none of these indices lend securities, and no revenues from securities lending were added to the performance shown. Performance shown is unaudited and subject to revision. This site may include materials and documents containing forward-looking statements which are based on our expectations and projections as of the date made. Past returns are not necessarily predictive of future returns.